H.C. Wainwright Sticks to Their Buy Rating for Xoma Corp

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Xoma Corp (NASDAQ: XOMA), with a price target of $49. The company’s shares closed yesterday at $24.55.

According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.0% and a 34.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $49.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.25 and a one-year low of $6. Currently, Xoma Corp has an average volume of 159.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from unique platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.